HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,559,588 | +6.9% | 250,251 | +0.9% | 0.01% | 0.0% |
| Q2 2023 | $8,944,639 | -36.7% | 247,980 | -33.0% | 0.01% | -38.5% |
| Q1 2023 | $14,138,434 | -34.6% | 370,213 | -2.5% | 0.01% | -27.8% |
| Q4 2022 | $21,606,865 | +75.9% | 379,734 | +22.2% | 0.02% | +63.6% |
| Q3 2022 | $12,283,000 | +5.7% | 310,657 | +17.6% | 0.01% | 0.0% |
| Q2 2022 | $11,622,000 | +2.0% | 264,136 | -7.6% | 0.01% | +22.2% |
| Q1 2022 | $11,396,000 | -8.5% | 285,769 | -7.7% | 0.01% | +12.5% |
| Q4 2021 | $12,449,000 | -2.9% | 309,604 | -1.8% | 0.01% | -20.0% |
| Q3 2021 | $12,824,000 | -10.3% | 315,235 | +0.1% | 0.01% | -9.1% |
| Q2 2021 | $14,302,000 | +2.8% | 314,959 | -5.6% | 0.01% | 0.0% |
| Q1 2021 | $13,909,000 | -4.3% | 333,621 | -1.9% | 0.01% | 0.0% |
| Q4 2020 | $14,531,000 | +76.9% | 340,223 | +8.9% | 0.01% | +57.1% |
| Q3 2020 | $8,213,000 | +1.0% | 312,518 | +3.0% | 0.01% | -12.5% |
| Q2 2020 | $8,134,000 | +50.3% | 303,383 | +0.9% | 0.01% | +14.3% |
| Q1 2020 | $5,411,000 | -43.4% | 300,774 | -44.2% | 0.01% | -22.2% |
| Q4 2019 | $9,560,000 | +107.7% | 539,202 | +81.7% | 0.01% | +80.0% |
| Q3 2019 | $4,603,000 | +64.0% | 296,776 | +81.7% | 0.01% | +66.7% |
| Q2 2019 | $2,807,000 | +9.9% | 163,376 | +3.0% | 0.00% | 0.0% |
| Q1 2019 | $2,553,000 | +8.6% | 158,602 | -1.3% | 0.00% | 0.0% |
| Q4 2018 | $2,351,000 | -28.2% | 160,702 | -10.9% | 0.00% | -25.0% |
| Q3 2018 | $3,276,000 | +2.8% | 180,281 | -4.6% | 0.00% | 0.0% |
| Q2 2018 | $3,188,000 | -16.7% | 189,002 | -3.3% | 0.00% | -20.0% |
| Q1 2018 | $3,828,000 | -7.7% | 195,400 | -4.6% | 0.01% | -16.7% |
| Q4 2017 | $4,149,000 | +20.8% | 204,800 | +3.6% | 0.01% | +20.0% |
| Q3 2017 | $3,434,000 | +37.7% | 197,700 | +1.6% | 0.01% | +25.0% |
| Q2 2017 | $2,493,000 | +1.1% | 194,500 | +2.2% | 0.00% | 0.0% |
| Q1 2017 | $2,466,000 | +25.8% | 190,300 | -4.1% | 0.00% | +33.3% |
| Q4 2016 | $1,961,000 | -18.2% | 198,500 | 0.0% | 0.00% | -25.0% |
| Q3 2016 | $2,398,000 | +31.0% | 198,500 | -6.4% | 0.00% | +33.3% |
| Q2 2016 | $1,830,000 | -11.6% | 212,100 | -3.0% | 0.00% | 0.0% |
| Q1 2016 | $2,071,000 | -53.3% | 218,700 | -14.4% | 0.00% | -57.1% |
| Q4 2015 | $4,430,000 | +42.2% | 255,600 | +10.2% | 0.01% | +40.0% |
| Q3 2015 | $3,116,000 | -40.5% | 232,000 | 0.0% | 0.01% | -37.5% |
| Q2 2015 | $5,239,000 | +56.0% | 232,000 | 0.0% | 0.01% | +60.0% |
| Q1 2015 | $3,359,000 | 0.0% | 232,000 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $3,359,000 | +59.1% | 232,000 | 0.0% | 0.01% | +66.7% |
| Q3 2014 | $2,111,000 | -7.9% | 232,000 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $2,292,000 | +16.8% | 232,000 | -2.0% | 0.00% | 0.0% |
| Q1 2014 | $1,962,000 | +4165.2% | 236,700 | +5565.4% | 0.00% | – |
| Q3 2013 | $46,000 | +39.4% | 4,178 | 0.0% | 0.00% | – |
| Q2 2013 | $33,000 | – | 4,178 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |